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Abstract
Background: SOX2 (Sry-box 2) is required to maintain a variety of stem cells, is overexpressed in some solid tumors, and is
expressed in epithelial cells of the lung.
Methodology/Principal Findings: We show that SOX2 is overexpressed in human squamous cell lung tumors and some
adenocarcinomas. We have generated mouse models in which Sox2 is upregulated in epithelial cells of the lung during
development and in the adult. In both cases, overexpression leads to extensive hyperplasia. In the terminal bronchioles, a
trachea-like pseudostratified epithelium develops with p63-positive cells underlying columnar cells. Over 12–34 weeks,
about half of the mice expressing the highest levels of Sox2 develop carcinoma. These tumors resemble adenocarcinoma
but express the squamous marker, Trp63 (p63).
Conclusions: These findings demonstrate that Sox2 overexpression both induces a proximal phenotype in the distal
airways/alveoli and leads to cancer.
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Introduction
Sox2 is a high mobility group transcription factor essential for
early mammalian development and for the maintenance of both
pluripotential embryonic stem cells and stem cells in multiple
adult tissues [1,2,3,4,5]. Overexpression of Sox2 has been
demonstrated in many different types of solid tumors
[6,7,8,9,10,11,12]. Recently, amplification of SOX2 has been
described in human squamous cell lung cancers [13,14,15].
However, data are lacking regarding a direct in vivo role for Sox2
in oncogenesis.
Sox2 plays important roles in lung epithelium. In the mouse,
Sox2 is expressed in lung epithelial cells, both in the embryonic
and adult trachea and airway/bronchiolar epithelium
[16,17,18,19]. Immunohistochemistry shows Sox2 protein in
tracheal basal cells, the p63-positive, undifferentiated progenitors
of the mucociliary epithelium [20], and in some, but not all,
columnar cells throughout the trachea and adult lung. Deletion of
Sox2 in the adult tracheal epithelium results in a reduction in the
proportion of basal cells and inhibits their ability to self renew,
both in culture and in vivo after injury by exposure to sulfur dioxide
(SO2) [17]. Sox2 is also important for maintenance of Clara cells,
ciliated cells, and goblet cells in the distal airway as Clara cell-
specific deletion late in development leads to a cuboidal epithelium
lacking these columnar cell types [19].
Given the importance of Sox2 in the maintenance of stem cell
phenotypes, its expression in lung epithelium, and its overexpres-
sion in a variety of tumors, we sought to define the potential role of
Sox2 in mouse and human lung cancer. We find that SOX2 is
overexpressed in human lung squamous cell carcinomas compared
with adenocarcinomas. We have used a new conditional allele of
the Rosa26 locus to overexpress Sox2 either during lung
development, using an SFTPC-Cre transgene, or in epithelial cells
of the adult lung using a Secretoglobin1a1(Scgb1a1)-CreER ‘‘knock-
in’’ allele [21]. In both models, we find extensive epithelial
hyperplasia, especially in the distal bronchioles and adjacent
alveoli, which progresses to carcinoma in about half the mice over
a period of weeks. In bronchi and at the bronchioalveolar duct
junction (BADJ), overexpression of Sox2 leads to development of a
pseudostratified epithelium, with p63-positive cells underlying
columnar cells. In the alveoli, hyperplasia develops which proceeds
to well-differentiated adenocarcinoma in about half of the mice.
Many of the hyperplastic cells stain positively for p63 and/or
Foxj1, and some cells become ciliated. Finally, in these regions
there is upregulation of Cyclin D1, a known target of Sox2 that
likely contributes to the abnormal proliferation of these cells.
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SOX2 is overexpressed in human squamous cell lung
cancer
We examined the expression of SOX2 in human lung tumors
using both transcriptional profiling and immunohistochemistry. An
expression microarray dataset of 89 early-stage lung cancers that
were resected at Duke University Medical Center was analyzed.
Unsupervised clustering of these data using the open-source
CLUSTER and TreeView software demonstrates that adenocarci-
nomas and squamous cell tumors cluster separately (data not
shown). Moreover, SOX2 is highly (5.9-fold) overexpressed in
squamous tumors when compared with adenocarcinomas
(p,.0001, data not shown). In addition, SOX2 is expressed in a
small subset of adenocarcinomas. These findings were verified using
a set of adenocarcinomas and squamous cell cancers from the
University of Michigan (n=281 (130 squamous, 151 adeno)) (data
not shown). These findings are consistent with previously-published
data from other groups [13,15]. We also obtained histologic slides
from the tumors in the Duke dataset for immunohistochemical
analysis. As shown in sections of representative tumors in Fig. 1A
and B, 15/20 squamous tumors stain strongly for SOX2. By
contrast, 4/20 adenocarcinoma samples stained positively for
SOX2 (Table S1). Additionally 17/20 squamous tumors, and 2/
20 foradenocarcinomas stained positively forp63(Trp63), a protein
involved in the self-renewal of stratified epithelial progenitors [22]
and a frequent marker of squamous cell cancer that clusters closely
withSOX2.In14of20squamoustumors,therewaspositivestaining
for both Sox2 and p63. No adenocarcinoma stained positively for
both SOX2 and p63, although others have demonstrated Sox2+/
p63+ staining in up to 12% of human adenocarcinomas [23]. We
next asked whether high SOX2 expression has prognostic signifi-
cance. Using the squamous tumors from the Duke dataset, tumors
with SOX2 expression above the median had a statistically-
significantly better prognosis than those with SOX2 expression
below the median (Fig. 2). However, this could not be repeated
using the Michigan squamous cell cancer samples.
Transgenic overexpression of Sox2 during lung
development
To directly test the effect of overexpression of Sox2 in vivo,w e
generated a new conditional allele of the Rosa26 locus (Rosa26-lox-
stop-loxSox2(Gt(Rosa)26Sor
tm1/Sox2/blh)(Fig. 3)(hereafter referred to as
Rosa26R-Sox2-IRES-GFP). In this allele, removal of the stop
cassette flanked by loxP sites leads to Sox2 expression under the
control of the Rosa26 locus. To increase the level of Sox2
transcription after recombination, we inserted a synthetic
cytomegalovirus early enhancer/chicken beta actin (CAG) pro-
moter upstream of Sox2. For identification of cells in which
recombination had occurred, we inserted an internal ribosomal
entry-enhanced green fluorescent protein (IRES-GFP) cassette
downstream of Sox2. To elucidate the effect of Sox2 overexpres-
sion in all epithelial cells of the lung during development, we
crossed Rosa26R-Sox2-IRES-GFP mice with mice carrying a
transgene in which Cre is driven by a regulatory region of the
human surfactant protein C gene (SFTPC). This transgene is
Figure 1. Sox 2 is upregulated in many human squamous cell
lung cancers and fewer adenocarcinomas. (A) Sections of a
representative squamous cell tumor and (B) adenocarcinoma stained
with anti-SOX2. The positively-staining tumor cells are surrounded by
negatively-staining stroma.
doi:10.1371/journal.pone.0011022.g001
Figure 2. Kaplan-Meier survival curve showing that Sox2
expression in squamous tumors is prognostic of better patient
survival times. P=.04 by log-rank test.
doi:10.1371/journal.pone.0011022.g002
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primary buds that will contribute to both the proximal and distal
postnatal lung [24]. Most of the SFTPC-Cre; Rosa26R-Sox2-IRES-
GFP mice were sacrificed within a few weeks of birth with
respiratory distress (for numbers see Materials and Methods).
Histologic analysis of a mouse that survived to 15 weeks after birth
showed very abnormal lung morphology with ectopic expression
of p63 throughout the bronchi and alveoli, and regions of
epithelial hyperplasia in the bronchi, bronchioles and alveoli as
described by others [16]. In addition, as demonstrated in Fig. 4,
regions of the lung parenchyma were almost completely replaced
by adenocarcinoma. Staining for phospho-histone-H3 reveals
increased proliferation of epithelial cells (5–8 per high-power
field(hpf)) in the Sox2-overexpressing lungs as compared to
controls (very rare cell per hpf) (data not shown).
Conditional overexpression of Sox2 in the adult lung
We next tested the effect of inducible overexpression of Sox2
in the lungs of adult mice. To do this, we used the
Figure 3. A schematic description of the Rosa26R-Sox2-IRES-GFP
allele targeting scheme.
doi:10.1371/journal.pone.0011022.g003
Figure 4. Sox2 overexpression during mouse lung development leads to epithelial hyperplasia and adenocarcinoma. (A) Section of
control 15 week post-natal Rosa26-Sox2-IRES-GFP lung stained with H&E. (B) High-power region of bronchus and adjacent alveoli of (A). (C) Section of
an SFTPC-Cre; Rosa26-Sox2-IRES-GFP transgenic mouse lung 15 weeks after birth stained with H&E. (D) A higher power view showing adenocarcinoma.
(A,C) Scale bars=200 microns. (B,D) Scale bars=50 microns.
doi:10.1371/journal.pone.0011022.g004
SOX2 and Lung Cancer
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Low-power and high-power magnifications of control homozygous Rosa26-Sox2-IRES-GFP lung stained with H&E. (C–F) Sections through the lung of
Scgb1a1-CreER; homozygous Rosa26-Sox2-IRES-GFP 18 weeks after tamoxifen injection. (C and E) Low-power view showing numerous regions of
adenocarcinoma throughout the lung. (D and F) High magnification showing glandular structure formation indicative of adenocarcinoma (arrows).
(A,C) Scale bars=500 microns. (B) Scale bar=50 microns. (D and F) Scale bar=100 microns. (E) Scale bar=250 microns.
doi:10.1371/journal.pone.0011022.g005
SOX2 and Lung Cancer
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epithelial cells expressing Scgb1a1 (CC10, CCSP). Previous studies
have shown that four injections of tamoxifen every other day, the
dose given here, result in recombination in approximately 80% of
Clara secretory cells of the airways of the lung extending down to
the bronchioalveolar duct junction and in some dual positive
Sftpc-Scgb1a1 epithelial cells in the alveoli adjacent to the BADJ
[21]. Mice were sacrificed at various times up to 34 weeks after the
tamoxifen injections.
We first analyzed the effect of Sox2 overexpression by
generating Scgb1a1-CreER mice heterozygous for the Rosa26R-
Sox2-IRES-GFP allele. At 6 weeks after tamoxifen injections, lungs
of these mice show no discernible abnormalities. However, by 13
weeks, bronchial epithelial hyperplasia developed near the BADJ.
Immunohistochemistry showed that about 50% of the cells in the
hyperplastic regions were positive for p63 at this time. In addition,
small groups of p63-positive cells were present in the alveoli (data
not shown). No p63 positive cells were seen in the airways of
control adult mice. At 18 weeks, the hyperplastic regions had not
progressed to cancer in these heterozygous mice.
In order to assess whether a higher level of Sox2 would lead to
cancer, we made the mice homozygous for the Rosa26R-Sox2-
IRES-GFP allele. These mice were sacrificed at various times from
6 to 34 weeks after the last tamoxifen injection. In all mice
examined at early stages (6 weeks after tamoxifen injection),
bronchial hyperplasia is seen at and just proximal to the BADJ,
and clusters of p63-positive cells develop at the BADJ and in the
alveoli (data not shown). Over the next 12–34 weeks, however,
both at the BADJ and in the alveoli, this hyperplasia progresses
into carcinoma in about half (9/22) of the mice (p,0.0001 when
compared to control mice by Chi square). A board-certified
human pathologist classified these tumors as well-differentiated
adenocarcinoma on standard hematoxylin and eosin staining
(Fig. 5 C–F). Relevant histologic features include lepidic growth of
the cells, back-to-back glandular-like structure formation, disrup-
tion of the normal septal architecture, and the impressively diffuse
replacement of normal parenchyma by cancer cells. In addition,
the bronchioles of these mice contain regions of pseudostratified
epithelium, with p63-positive cells (Fig. 6) underlying columnar
cells. However, these cells did not stain positively for the basal cell
markers Keratin 14 and Nerve Growth Factor Receptor (NGFR).
By contrast, no phenotypic changes are seen in the trachea and
large bronchi at any time.
The level of Sox2 expression in cells after recombination was
tested by isolation of GFP-positive cells by FACS from Scgb1a1-
CreER; Rosa26R-Sox2-IRES-GFP lungs. As a control we isolated
cells from Scgb1a1-CreER mice homozygous for a Rosa26R
FGFP
reporter allele. Quantitative PCR of the two populations showed
an increase in mean normalized expression of 40 fold in Scgb1a1-
CreER; Rosa26-Sox2-IRES-GFP cells vs. wild type (Fig. 7D).
Significantly, this level of expression was seen at both 1 week
and 34 weeks after tamoxifen administration, and there was no
significant difference in expression levels in cells from mice with
hyperplasia only compared with those with tumors. These
observations suggest that progression of hyperplasia to carcinoma
is not due to an increase in the expression level of Sox2 but is more
likely associated with secondary changes in the epithelial cells. The
fact that only about half of the mice (9/22) develop tumors
suggests that modifier genes may be important in tumor
progression.
Immunohistochemical analysis of the tumors for bronchial
epithelial markers was then performed. As expected, immunohis-
tochemistry of lungs in homozygous Rosa26R-Sox2-IRES-GFP mice
demonstrates high levels of recombination as measured by GFP
expression and Sox2 protein within the conducting airways,
BADJs and the alveolar tumors (Fig. 7A–C). Although Sox2 is
inducibly overexpressed in Scgb1a1-expressing cells, Scgb1a1
expression gradually decreases over time, eventually becoming
completely absent at late stages of tumor development (Fig. 8A–C).
This was confirmed by quantitative PCR of sorted cells, which
demonstrates that Scgb1a1 expression is diminished 100-fold
(Fig. 8D). The tumors do not stain for the type II cell marker Sftpc.
Surprisingly, many of the cells that comprise the hyperplastic
regions and eventual adenocarcinomas in the alveoli stain
positively for the ciliated cell markers Foxj1 and acetylated tubulin
(Fig. 9). In addition, approximately 50% of the tumor cells stain
Figure 6. High-power images of bronchi of (A) a Scgb1a1-CreER;
homozygous Rosa26-Sox2-IRES-GFP and (B) a homozygous Rosa26-
Sox2-IRES-GFP control mouse lung 18 weeks after tamoxifen
injection stained with anti-E cadherin (red) and anti-p63
(green) demonstrating the appearance of a layer of p63-
positive cells underlying columnar cells. Scale bars=50 microns.
doi:10.1371/journal.pone.0011022.g006
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magnifications of Scgb1a1-CreER; homozygous Rosa26-Sox2-IRES-GFP lung 18 weeks after tamoxifen injection stained for GFP and Sox2. Concurrent
staining of Sox2 (red) with GFP (green) is demonstrated in the conducting airways (A), BADJs (B), and peripheral tumors in the alveoli (C). (D) QPCR
shows that Sox2 is overexpressed approximately 40 fold in cells sorted by GFP expression. (A–C) Scale bars=100 microns.
doi:10.1371/journal.pone.0011022.g007
Figure 8. Immunohistochemical analysis of Scgb1a1 and Sftpc (proSP-C) expression in tumors and conducting airways. Scgb1a1 (red)
expression is downregulated within the conducting airways by 12 weeks after tamoxifen injection (A). However, expression is initially maintained
within the tumors at 12 weeks (B). By 18 weeks, expression of Scgb1a1 is completely lost within the tumors and lung (C). Orange cells within panel C
are autofluorescent macrophages. Sftpc (proSP-C) (green) expression is not noted within the tumors at any stage. (D) QPCR confirms the
downregulation of Scgb1a1 within Scgb1a1-CreER; homozygous Rosa26-Sox2-IRES-GFP lung 18 weeks after tamoxifen injection. (A and C) Scale
bar=100 microns. (B) Scale bar=50 microns.
doi:10.1371/journal.pone.0011022.g008
SOX2 and Lung Cancer
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confirmed by quantitative PCR that showed upregulation in
Scgb1a1-CreER; Rosa26-Sox2-IRES-GFP cells (Fig. 10).
In order to assess the transcriptional similarity of the alveolar
carcinomas to human squamous cell lung cancer, we performed
quantitative PCR for additional transcripts that cluster closely with
Sox2 in the Duke lung cancer microarray dataset. As Fig. 11
demonstrates, FoxE1 and Desmoglein, are statistically-significantly
upregulated in the Scgb1a1-Rosa26-Sox2-IRES-GFP tumor cells
compared with wild-type Scgb1a1-positive cells. Snai2 is also
upregulated in the tumor cells. Thus, although the tumors were
classified as adenocarcinomas, they contain a significant propor-
tion of cells that express squamous cell markers in addition to p63.
To begin to elucidate the mechanism of Sox2-induced
neoplasia, we stained sections of tumors from Scgb1a1-CreER;
homozygous Rosa26R-Sox2-IRES-GFP lungs for Cyclin D1, a target
of Sox2 in breast cancer cell lines [25]. As Fig. 12A–D
demonstrates, approximately 90% of hyperplastic cells in the
alveoli stain positively for Cyclin D1. Control lungs show Cyclin
D1 staining only in some bronchial epithelial cells. This likely
explains the increased proliferation of the Sox2-overexpressing
cells as Cyclin D1 is known to promote G0/G1-to-S transition in
the cell cycle.
In order to determine which cells within the tumor were
proliferating, we co-stained sections for phosphohistone-H3 and
p63 or FoxJ1. Significantly, we found that all phosphohistone-H3
positive cells within the tumors were also positive for p63 and for
FoxJ1 (Fig. 13 A–B) indirectly suggesting that the proliferative cells
may be progenitors that co-express both transcription factors. As
Fig. 13C demonstrates, none of the ciliated cells in the tumors
stained positively for phosphohistone-H3.
Discussion
We have directly demonstrated in vivo that overexpression of Sox2
is oncogenic. Current mouse models of lung cancer are almost
exclusively adenocarcinoma [26]. In contrast to human tumors,
mouse tumors have less stromal response and metastasize less
Figure 9. Expression of ciliated cell markers in Sox2 overexpressing tumors. (A and B) Cilia are expressed on the apical surfaces of Sox2
positive (green) tumor cells as shown by acetylated tubulin staining (red). (C–E) FoxJ1(red) is expressed in a subset of Sox2 (green) positive tumor
cells. (A) Scale bar=125 microns. (B) Scale bar=25 microns. (C–E) Scale bar=50 microns.
doi:10.1371/journal.pone.0011022.g009
SOX2 and Lung Cancer
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cells drives development of histologically well differentiated adeno-
carcinoma with significant squamous cell features including wide-
spread expression of p63, FoxE1 and Desmoglein3. This mixed
phenotype is not unique to tumors induced by Sox2. Inducible
deletionofthetumorsuppressorLkb1 along with inducible expression
of oncogenic K-Ras leads to adenocarcinoma with squamous features
[27] as well. One possibility for this mixed phenotype in our model is
that while Sox2 alone can drive expression of some squamous tumor
markers, an additional oncogenic stimulus, - ‘‘a second hit’’ - may be
required to drive complete squamous differentiation. Noticeably
missing from our model are cytokeratins 5 and 14, markers of
squamous cell cancer, which may account for the lack of
characteristic squamous features on H&E.
We speculate that cell-of-origin may also contribute to
differences between tumors arising in these locations and that
expression of the conditional Sox2 allele in other respiratory
epithelial cells will lead to tumors of different phenotypes. We are
therefore continuing to investigate whether different cell types of
origin may result in tumors with more squamous features.
It has been suggested that lung adenocarcinoma may arise from
Scgb1a1, Sftpc dual positive putative bronchial alveolar stem cells
(BASCs), that reside near the BADJ. Our findings are consistent with
the idea that this population is more susceptible to tumorigenesis than
the majority of cells within the epithelium in which Sox2 is
overexpressed. This is supported by the observation that only
hyperplasia develops within the conducting airways while adenocar-
cinoma forms at the BADJ. However, a model in which BASCs are
the only cancer-initiating cell is overly simplistic. We note extensive
tumor formation in the alveoli, and evidence from lineage tracing for
the presence of cells that contribute descendants to both bronchioles
and alveoli in vivo is still lacking [21]. We note that human squamous
cell tumors have been classified into proximal and distal types [28]. It
is likely that the very peripheral tumors develop from Scgb1a1-
positive cells that already reside within the alveoli in a different
microenvironment than the cells within the bronchioles.
The mechanism of Sox2’s oncogenic ability is unclear and will be
the focus of future investigation. CyclinD1 expression is clearly
induced in our model. The CCND1 gene has a SOX2-binding
sequence in its promoter, and chromatin immunoprecipitation has
revealed SOX2 and beta-catenin cooperative binding regulating
this promoter in breast cancer cell lines [25]. Directly overexpress-
ing Cyclin D1 in mammary tissue in transgenic mice using the
mouse mammary tumor virus (MMTV) promoter leads to breast
cancer, demonstrating that Cyclin D1 is sufficient for tumorigenesis
[29]. Finally, Cyclin D1 is necessary to effect transformation of cells
downstream of specific oncogenic stimuli [30]. Further character-
ization of the transcriptional targets of Sox2 as well as downstream
events in Sox2-transformed Clara cells is continuing.
Figure 10. Expression of p63 in Sox2 overexpressing tumors.
(A) p63 (red) is expressed in a subset of Sox2 overexpressing tumor cells
as marked by GFP (green) expression. (B) p63 upregulation is confirmed
by QPCR. (A) Scale bar=100 microns.
doi:10.1371/journal.pone.0011022.g010
Figure 11. QPCR shows that Sox2 overexpressing cells
upregulate a number of squamous cell cancer markers
including FoxE1, Desmoglein3, and Snai2.
doi:10.1371/journal.pone.0011022.g011
SOX2 and Lung Cancer
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SOX2 may induce a stem-like transcriptional program and has been
demonstrated to be upregulated in poorly-differentiated adenocarci-
nomas by genomic analyses [31,32]. A recent study has demonstrated
that a SOX2+/p63- immunohistochemical profile correlates with
high-grade histology across non-small cell lung cancer subtypes [23].
In the Duke dataset, patients with squamous tumors with expression
of SOX2 mRNA above the median enjoyed a better prognosis than
those with lower levels of expression. The reasons for this discrepancy
are unclear. However, they may relate to differences between tumor
types included in the datasets: SOX2 may play different roles in
squamous cell tumors and adenocarcinomas. Such issues will be
studied further in the future as Sox2 is inducibly expressed in other
bronchial epithelial cell types in the mouse.
An important feature of our model is that overexpression of
Sox2 leads not only to distal hyperplasia and cancer but also to
development of a pseudostratified epithelium with p63-positive
cells adjacent to the basal lamina and FoxJ1 cilliated cells
reaching to the apical surface. This epithelial metaplasia is seen
both proximal to the BADJ and in larger bronchioles/bronchi.
This result suggests that high levels of Sox2 can lead to
transdifferentiation of Scgb1a1-positive cells (and/or their
daughters) into basal-like and ciliated cells. Whether all or
only a subset of Scgb1a1-positive cells throughout the
intralobar airway are able to undergo this transformation is
not yet known. In addition, it will be important to determine
whether the p63 isoform expressed is deltaNp63 or TA-p63 and
whether p63 and FoxJ1 are direct downstream targets of Sox2.
We note that the p63 promoter contains 3 conserved Sox2
c o n s e n s u ss i t e s .M o r e o v e r ,ar e c e n tr e p o r td e m o n s t r a t e d
squamous metaplasia of the alveoli of the lung by overexpres-
sion of deltaNp63 downstream of a tetracycline-inducible SftpC
promoter [33].
Initially, the expression of cilia within the Sox2 overexpressing
tumors seemed to confound Sox2 overexpression in Scgb1a1
positive cells as a model of human cancer. However a recent
report suggests that this may not be the case [34]. They report
three cases of well-differentiated adenocarcinoma that feature a
bland cytological appearance, prominent ciliated cells and
express p63. It is very likely that lack of reporting of ciliated
Figure 12. CyclinD1 is highly-expressed in Sox2-overexpressing lungs, and Sox2 overexpression leads to a pseudostratified
epithelium. (A) Low-power image of a control lung demonstrating expression of Cyclin D1 restricted to a few bronchial cells. (B) High-power image
of (A). (C) Low-power images of anti-Cyclin D1 immunohistochemistry of sections of a Scgb1a1CreER- Rosa26Sox2-IRES-GFP transgenic lung 12 weeks
after tamoxifen injection demonstrating high expression of Cyclin D1 in hyperplastic alveolar clusters. (D) High-power image of (C). (A–D) Scale
bars=100 microns.
doi:10.1371/journal.pone.0011022.g012
SOX2 and Lung Cancer
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due to the simple fact that cilia is not a feature commonly looked
for during histology of resected human tumors.
Given the possibility that a proportion of human non-small cell
lung cancers arise from SOX2 upregulation, this and future mouse
models will be useful in testing existing and new therapeutics for
this group of patients. From a translational perspective, charac-
terization of oncogenic stimuli in specific potential cells-of-origin of
lung cancer is an important step toward designing individualized
therapies for human lung cancer patients.
Materials and Methods
Ethics Statement
All mouse work was performed according to the requirements of
the Duke University Institutional Care and Use Committee
(IACUC). Mouse husbandry, breeding, genotyping, tamoxifen
injection, and euthanasia specifically for these experiments were
approved via protocol number A226-07-08. Euthanasia was
performed by CO2 asphixiation.
Microarray Analysis
The publicly-available microarray data (accession number
GSE3141 NCI GEO) from lung cancer patients resected at Duke
was obtained and RMA-normalized using the publicly-available
RMAExpress program (rmaexpress.bmbolstad.com/). The expres-
sion of SOX2 was compared between adenocarcinomas and
squamous cell carcinomas using a two-tailed t test. For Kaplan-
Meier analysis, the median expression of SOX2 was determined
across squamous cell tumors. The squamous cases were then
grouped in a binary fashion with respect to expression of SOX2
above or below the median. SAS Version 9 with Enterprise Guide
4.0 was used to perform the survival analysis with log rank test to
determine significant difference.
Mice
The SFTPC-Cre and Scgb1a1-CreER lines have been described
previously (Okubo et al. 2005; Rawlins et al. 2009b). The
Rosa26R-Sox2-IRES-GFP and Rosa26R-FGFP alleles where gener-
ated by inserting a CAG–loxP-STOP-LoxP-Sox2 –IRESGFP-
polyA and CAG-loxP-STOP-loxP-eGFP-f-polyA (eGFP-f=farne-
sylated eGFP) cassettes respectively into a Rosa-acceptor targeting
plasmid. Mouse lines where generated by homologous recombi-
nation in 129/SvEv embryonic stem cells followed by injection
into C57/Bl6 blastocysts. Chimeras were bred for germline
transmission. The mice were maintained on a mixed 129/
SvEvxC57/Bl6 mixed background. Tamoxifen injections were
carried out at 6 weeks of age at a dose of 0.25 mg/kg body weight
in corn oil delivered intraperitoneally every other day for four
injections. GFP reporter activity (GFP and eGFP-f) is detected
only after Cre-mediated recombination of the LoxP sites.
For the SFTPC-Cre; Rosa26R
Sox2-IRES-GFP/+ experiments, three mice
were moribund at postnatal day (P) 11 and one at P16. Of the
remaining mice, one was sacrificed at 12 weeks, and one at 15 weeks.
For the Scgb1a1-CreER; Rosa26R
Sox2-IRES-GFP/+ experiments,
mice were sacrificed at various times from 6 weeks, 12/13 weeks,
and 18 weeks after tamoxifen injection. For the Scgb1a1-CreER;
Rosa26R
Sox2-IRES-GFP/Rosa26RSox2-IRES-GFP experiments, mice were
Figure 13. Actively proliferating cells 18 weeks after tamoxifen
as marked by Phosphohistone H3 (red) (arrows) staining are
both FoxJ1 (green) positive (A) and p63 (green) positive (B). (C)
High-power image demonstrating that Phosphohistone-H3-positive
cells (red) (arrow) do not stain for acetylated tubulin (purple). Cell
membrane is marked by beta-Catenin (green). (A,B) Scale bars=100
microns. (C) Scale bar=25 microns.
doi:10.1371/journal.pone.0011022.g013
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after tamoxifen injection (Table S1).
Representative sections of the abnormal lungs were reviewed
with a board certified lung pathologist with experience in mouse
lung pathology.
Immunohistochemistry
Paraffin sections were stained with the following antibodies: rabbit
anti-Sox2 (1:1500, Seven Hills Bioreagents), mouse anti-p63 (1:250,
Santa Cruz), rat anti-phophohistone-H3 (1:500, Upstate), goat anti-
Scgb1a1 (1:10,000, kind gift of Dr. Barry Stripp), rabbit anti-Sftpc
(pro-SPC) (1:500, Millipore), chicken anti-GFP (1:500 Aves Labs), rat
anti-E-Cadherin (1:1000, Zymed), mouse anti-acetylated tubulin
(1:100, Sigma-Aldrich), mouse anti-Foxj1 (1:1000, eBioscience),
rabbit abti-beta Catenin (1:1000, Sigma-Aldrich), and rabbit anti-
CyclinD1 (1:1000, Cell Signaling). For fresh tumor staining and
CyclinD1 staining, biotinylated secondary antibody was used
followed detection with the ABC kit (Vectorlabs). For fluorescent
staining, Alexa-Fluor coupled secondary antibodies (Invitrogen) were
used at 1:500. Z-stacks of optical sections were captured on a Leica
Sp2 laser scanning confocal microscope. Multiple optical sections
were scored manually to distinguish cell boundaries.
For human tumor SOX2 analysis, each stained slide was
evaluated by 2 observers blinded to histology and microarray
expression level. Positive staining was called when greater than 5%
of nuclei stained positively.
Cell Sorting and qPCR
Quantitative PCR (qPCR) was performed on mRNA isolated
from Sox2 lung epithelial cells isolated from Scgb1a1-CreER;
Rosa26R
Sox2-IRES-GFP/Sox2-IRES-GFP and Scgb1a1-CreER; Ro-
sa26R
FGFP/FGFP mice. Single cell suspensions of lung epithelial
cells were prepared as described elsewhere (Teisanu et.al. 2009).
Cells were sorted based on GFP expression using a BD
FACSVantage cell sorter. RNA was then extracted from the
sorted cells using the Qiagen RNeasy kit, treated with DNase I,
and cDNA was synthesized using the Bio-Rad iScript cDNA
synthesis kit. qPCR was performed on an Eppendorf Mastercycler
ep realplex real-time PCR system using the following Taqman
primer probe sets from Applied Biosystems; Sox2 -
Mm00488369_s1, Scgb1a1-Mm00442046_m1, Trp63-
Mm00495788_m1, Krt14-Mm00516876_m1, and Gusb-
Mm00446953_m1. Beta glucuronidase (Gusb) served as the
reference control.
Supporting Information
Table S1 Annotation of microarray and histologic samples.
Found at: doi:10.1371/journal.pone.0011022.s001 (0.03 MB
)
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